Continuing Medical Education: Primary Care CME 2010: Neurology CME 2010: Advances in the Treatment of Schizophrenia: New Approaches: Live Webcast: November 16, 2010 - November 16, 2011
http://www.cmenetworks.com/cme/11666/1/Continuing-Medical-Education-Primary-Care-CME-2010--Neurology-CME-2010--Advances-in-the-Treatment-of-Schizophrenia-New-Approaches-Live-Webcast-November-16-2010---November-16-2011/Page1.html
CME Outfitters
CME Outfitters is an independent accredited healthcare communications agency providing multidisciplinary continuing medical education content development, production, marketing, accreditation, and project management services to the healthcare industry.
By CME Outfitters
Published on 10/28/2010
Advances in the Treatment of Schizophrenia: New Approaches
CME Outfitters, LLC
November 16, 2010 - November 16, 2011
In this neuroscienceCME Live and On Demand, the experts will provide clinically relevant practice points for the early identification and clinical management of schizophrenia.
CME Sponsor:
CME Outfitters, LLC
Location: Live Webinar
Course Directors/Instructors:
Donald C. Goff, MD
Professor of Psychiatry
Harvard Medical School
Director, Schizophrenia Program
Massachusetts General Hospital
Boston, MA
Philip D. Harvey, PhD
Professor of Psychiatry and Behavioral Sciences
University of Miami Miller School of Medicine
Miami, FL
Number of Credits:
1.5 AMA PRA Category 1 Credits™
Registration Fee: Free
More Info
Detailed Description:
A critical component of recovery in schizophrenia is functional remission. Recovery requires effort on the part of patients and support from caregivers to bypass societal barriers and reach functional objectives. Clinicians must learn strategies to achieve functional remission, consistently measure functional change in their patients, and work with patients to raise the bar toward achieving functional remission. Clinicians must know specific distinctions in efficacies of antipsychotic agents.
As we increasingly broaden our treatment goals from an exclusive focus on effectiveness to improving quality of life, minimizing drug side effects and medical complications becomes a high priority of treatment. In addition, selection of an antipsychotic agent often involves a balance among optimal efficacy, safety, and tolerability for an individual patient.
This neuroscienceCME Webcast will address a comprehensive approach in the choice of antipsychotic agent and measurement of functioning in the treatment of schizophrenia. The activity will review the relationships among side effects, adherence, and medical morbidity. It will specifically address the side effect profiles of the new-generation agents while discussing strategies to minimize their side effects and medical risk.
Learning Objectives:
At the end of this CE activity, participants should be able to:
Physicians, physician assistants, nurses, nurse practitioners, pharmacists, psychologists, social workers, certified case managers, and other health care professionals with an interest in schizophrenia
Advances in the Treatment of Schizophrenia: New Approaches
CME Outfitters, LLC
November 16, 2010 - November 16, 2011
In this neuroscienceCME Live and On Demand, the experts will provide clinically relevant practice points for the early identification and clinical management of schizophrenia.
Advances in the Treatment of Schizophrenia: New Approaches
CME Sponsor:
CME Outfitters, LLC
Location: Live Webinar
Course Directors/Instructors:
Donald C. Goff, MD
Professor of Psychiatry
Harvard Medical School
Director, Schizophrenia Program
Massachusetts General Hospital
Boston, MA
Philip D. Harvey, PhD
Professor of Psychiatry and Behavioral Sciences
University of Miami Miller School of Medicine
Miami, FL
Number of Credits:
1.5 AMA PRA Category 1 Credits™
Registration Fee: Free
More Info
Detailed Description:
A critical component of recovery in schizophrenia is functional remission. Recovery requires effort on the part of patients and support from caregivers to bypass societal barriers and reach functional objectives. Clinicians must learn strategies to achieve functional remission, consistently measure functional change in their patients, and work with patients to raise the bar toward achieving functional remission. Clinicians must know specific distinctions in efficacies of antipsychotic agents.
As we increasingly broaden our treatment goals from an exclusive focus on effectiveness to improving quality of life, minimizing drug side effects and medical complications becomes a high priority of treatment. In addition, selection of an antipsychotic agent often involves a balance among optimal efficacy, safety, and tolerability for an individual patient.
This neuroscienceCME Webcast will address a comprehensive approach in the choice of antipsychotic agent and measurement of functioning in the treatment of schizophrenia. The activity will review the relationships among side effects, adherence, and medical morbidity. It will specifically address the side effect profiles of the new-generation agents while discussing strategies to minimize their side effects and medical risk.
Learning Objectives:
At the end of this CE activity, participants should be able to:
- Identify signs and symptoms of prodromal and first-episode psychosis that typically would be seen and could be recognized by both primary care physicians and psychiatrists.
- Customize a medication plan for patients with schizophrenia that uses a structured screening tool to detect lack of adherence and considers tolerability and ease of administration.
- Design a multimodal, individualized treatment and monitoring plan that specifies assessment tool, medication therapy, behavioral therapy, and follow-up regimen for patients with schizophrenia.
Physicians, physician assistants, nurses, nurse practitioners, pharmacists, psychologists, social workers, certified case managers, and other health care professionals with an interest in schizophrenia